Stemcell United Ltd. (OSS) AI Stock Analysis

Stemcell United Ltd.

(ASX:OSS)

Select Model

Rating:37Underperform

Price Target:AUD 0.01▼(-14.29% Downside)

Action:reiterated

Date:10/06/26

The overall score is at the minimum of 37, reflecting a company in severe financial distress. The most significant factor is the fundamental unprofitability and technical insolvency, with a negative gross margin and accelerating cash burn threatening its viability. The lack of meaningful technical or valuation support reinforces the extreme risk profile.

Positive Factors

Revenue reboundThe sharp revenue rebound indicates improved commercial traction and a stronger level of customer activity than in the prior year. If maintained, a larger revenue base could provide operating leverage and create a foundation for future margin improvement, although profitability is not yet established.

Negative Factors

Negative gross profitNegative gross profit means the company is not yet covering the direct costs associated with its revenue, leaving little foundation for sustainable operating earnings. Unless product economics improve materially, further revenue growth may continue to generate losses rather than strengthen cash generation.

Stemcell United Ltd. (OSS) vs. iShares MSCI Australia ETF (EWA)

Market Cap: AUD 3.29M
Dividend Yield: ―
Average Volume (3M): 480.86K
Price to Earnings (P/E): -3.2
Beta (1Y): -0.54
Revenue Growth: 877.51%
EPS Growth: 67.42%
Country: Australia
Employees: 31
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Stemcell United Ltd. Business Overview & Revenue Model

Company Description

BPH Global Ltd, along with its associated entities, specializes in the procurement, production, promotion, and sale of traditional medicinal items. Its operational reach spans Australia, Singapore, China, and the broader Southeast Asian market. The c...

How the Company Makes Money

null

Stemcell United Ltd. Financial Statement Overview

Summary

Financial health is critically weak. The company is technically insolvent with negative equity, deeply unprofitable with negative gross margins, and burning cash at an accelerating rate. The recent revenue surge is the only positive, but it is generating larger absolute losses.

Income Statement

18Very Negative

Balance Sheet

10Very Negative

Cash Flow

15Very Negative

Financial statement breakdown
Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	3.44M	3.44M	352.38K	109.97K	339	14.35M
Gross Profit	-890.49K	-890.49K	-678.01K	18.27K	339	2.29M
EBITDA	-1.76M	-1.76M	-1.45M	-1.76M	-3.52M	-2.49M
Net Income	-1.79M	-1.79M	-1.49M	-2.27M	-4.32M	-3.54M
Balance Sheet
Total Assets	1.38M	1.38M	541.00K	691.84K	2.10M	7.16M
Cash, Cash Equivalents and Short-Term Investments	259.88K	259.88K	152.74K	134.82K	1.14M	685.56K
Total Debt	555.74K	555.74K	0	508.64K	0	1.30M
Total Liabilities	2.26M	2.26M	2.01M	1.97M	1.19M	2.44M
Stockholders Equity	-868.82K	-868.82K	-1.45M	-966.82K	530.13K	3.20M
Cash Flow
Free Cash Flow	-2.14M	-2.14M	-932.18K	-1.26M	-1.49M	-4.93M
Operating Cash Flow	-2.14M	-2.14M	-929.81K	0	0	0
Investing Cash Flow	-8,382	-8,382	-2,366	185.33K	6,291	-914.21K
Financing Cash Flow	2.44M	2.44M	962.99K	697.04K	1.38M	281.27K

Stemcell United Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

AU:OSS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:MSB	64Neutral	AUD 2.94B	-35.83	-10.06%	―	555.67%	49.08%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:CMB	51Neutral	AUD 11.77M	-1.59	-247.44%	―	-4.24%	33.39%
AU:OCC	50Neutral	AUD 149.82M	-10.38	-36.83%	―	51.07%	-47.63%
AU:CYP	42Neutral	AUD 4.02M	-0.31	-617.89%	―	―	13.67%
AU:1AI	40Underperform	AUD 20.28M	-5.71	-132.20%	―	―	-200.00%
AU:OSS	37Underperform	AUD 3.29M	-3.17	216.63%	―	877.51%	67.42%

* Healthcare Sector Average

Performance Comparison

AU:OSS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
AU:OSS	Stemcell United Ltd.	0.01	-0.01	-30.00%
AU:CYP	Cynata Therapeutics Limited	0.01	-0.22	-94.78%
AU:1AI	Living Cell Technologies Ltd.	0.01	0.00	0.00%
AU:MSB	Mesoblast Limited	2.26	-0.22	-8.87%
AU:OCC	Orthocell Ltd	0.55	-0.64	-53.78%
AU:CMB	Regeneus Ltd.	0.40	-0.09	-19.19%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 06, 2026

Stemcell United Ltd. AI Stock Analysis